Stefan Bourgeois
Antwerpen, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 49 publications
Corrigendum to 'Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: Insights from a multicenter European cohort' [JHEP Reports (2026) 19;8(8):101898].
Journal: JHEP reports : innovation in hepatology
Published: September 03, 2026
A randomized trial of viral vector and adjuvanted protein HBV therapeutic vaccine in people with chronic hepatitis B on nucleos(t)ide analogs.
Journal: Hepatology communications
Published: March 20, 2026
Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: Insights from a multicenter European cohort.
Journal: JHEP reports : innovation in hepatology
Published: November 20, 2025
Progression to cirrhosis in chronic hepatitis D with mild-to-moderate fibrosis: Insights from a multicenter European cohort.
Journal: JHEP reports : innovation in hepatology
Published: November 20, 2025
Clinical Trial: Hepatitis B Virus Genotype and a Combination of End-of-Treatment Biomarkers Predict Severe Flares After Nucleos(t)ide Analogue Cessation.
Journal: Alimentary pharmacology & therapeutics
Published: September 04, 2025
A liver gene signature links liver cancer risk in chronic viral hepatitis to intrahepatic IgA plasma cells.
Journal: JHEP reports : innovation in hepatology
Published: May 20, 2025
Severe Liver-Related Outcomes in Patients With Hepatitis Delta: Results From a Multi-Ethnic Multicenter Long-Term Follow-Up Study.
Journal: Journal of viral hepatitis
Published: September 17, 2024
Comprehensive alpha, beta, and delta cell transcriptomics reveal an association of cellular aging with MHC class I upregulation.
Journal: Molecular metabolism
Published: May 08, 2024
The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis.
Journal: Journal of viral hepatitis
Published: October 10, 2022
Correction to: Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir.
Journal: Infectious diseases and therapy
Published: September 16, 2021
Last Updated: 09/26/2026